Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method

FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.

PharmaDrug’s (CSE: PHRX) subsidiary SecureDose has finally revealed its first biosynthetic formulation: pharmaceutical grade cocaine.

SecureDose is reportedly initiating work on a novel manufacturing method for the commercial-scale production of cocaine, which will be produced to support safe supply programs.

“We have seen the proliferation of safe supply programs in both Canada and around the world. While opioid addiction is a serious problem, there exists a supply chain that provides both natural and synthetic opioid products for those programs,” commented Robert Steen, CEO of PharmaDrug.

“Cocaine, however, is the illegal drug that causes the most cost and harm to society barring opioids according to the Canadian Centre for Substance Use and Addiction, causing $4.2 Billion1 in harm in Canada annually – but there is no supply chain to alleviate these harms.”

READ: PharmaDrug Names Dr David Kideckel As Chairman, While SecureDose Finalizes Formulation

A patent has been filed for a method of development that uses biosynthetic chemistry that the company believes will allow for the use of GMP manufacturing in the production of pharmaceutical grade cocaine. The intent is that the resulting product will be a reliable, regulated, clinically manufactured product that is suitable for use in safe supply programs.

A lab has already been identified by the company that will be used for the development of the novel process. An accelerated development timeframe is being pursued by the lab, with the manufacturing process to target the cost effective and efficient production of cocaine.

PharmaDrug last traded at $0.06 on the CSE.


FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The $30,000 Gold Case Just Got Stronger | Simon Marcotte

Why Silver’s Move Is ‘Scary’ to Some Miners | Frank Basa

Are Commodities Entering a Generational Cycle? | Terry Lynch

Recommended

Steadright Closes Out Financing, Raising $1.6 Million For Moroccan Strategy

Questcorp and Riverside Lock Down Key Sonora Mineral Concessions

Related News

PharmaDrug: A Path To Safe Supply

In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company's groundbreaking biosynthetic...
Wednesday, March 13, 2024, 01:30:00 PM

Aura Health Completes Name Change to Pharmadrug Inc

Aura Health (CSE: BUZZ) announced this morning that it has completed its name change to...

Monday, October 21, 2019, 09:28:36 AM

PharmaDrug Subsidiary Begins Prep Work For Clinical Trial Of PD-001 For Viral Infectious Diseases

PharmaDrug (CSE: PHRX) yesterday reported that its joint venture, Sairiyo Therapeutics, has begun the process...
Friday, September 20, 2024, 08:29:02 AM

PharmaDrug: Biosynthetic Pharma-Grade Cocaine

PharmaDrug Inc (CSE: PHRX) last month revealed that it has begun work on developing a...
Sunday, April 7, 2024, 01:14:41 PM

PharmaDrug Anticipates Biosynthetic Cocaine Commercial-Scale Production In As Little As 12 Months

PharmaDrug Inc (CSE: PHRX) has established a strategic plan to push forward with its intent...
Monday, May 13, 2024, 08:55:00 AM